PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
A Cammarota, SK Kamarajah, S Markar, EC Smyth · 2024
Read PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials by A Cammarota, SK Kamarajah, S Markar, EC Smyth (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12836520.txt.
Description
Cammarota, Kamarajah, Markar, and Smyth meta-analyze PD-L1 as a response marker in operable stomach and esophagus cancer, in a study from twenty twenty-four. Adding immune checkpoint drugs to chemotherapy before surgery is under study. Fifteen randomized trials with over six thousand patients are pooled. Pathological response and survival links are quantified.
Chemo plus immune drugs triple the odds of complete pathological response. Response predicts survival weakly overall but better in recent trials. PD-L1 level five or higher significantly predicts complete response. Stratifying patients by PD-L1 is supported by the pooled evidence. Biomarker-selected trial designs are the recommended next step.
Catalog record
| CREATOR | A Cammarota, SK Kamarajah, S Markar, EC Smyth |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |